In this issue of Deep Dive we look at innovation in pharma R&D, asking how can pharmaceutical companies change up the development model with new strategies and technologies to cut waste
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.